Dr. Susan O'Dwyer:

That is a question for the HSE. When new drugs are approved, sometimes they are given a restricted approval and certain conditions apply to that approval. By approval, I mean funding under community drug schemes. In this instance, the HSE has said that for this particular medication, consultant initiation is appropriate and that is the approval mechanism it has put in place.